S& P 500 hits all time highs U.S.-Japan trade deal optimism
Investing.com -- Tate & Lyle (LON:TATE), the UK-based food and beverage ingredient supplier, on Tuesday confirmed that its FY25 results for the core business are in line with the reduced forecast it issued in February.
The company reported a 5% organic revenue decline and a 4% increase in EBITDA, which aligns with the Q3 guidance for FY25 EBITDA growth at the lower end of the 4-7% range.
Shares of Tate & Lyle rose 3.5% to 521 pence.
In addition, the integration of CP Kelco, a global leader in nature-based ingredient solutions, appears to be progressing well. CP Kelco’s EBITDA margin increased by 90 basis points in FY25, surpassing the acquisition plan’s expectations.
Despite a restatement of the FY24 baseline EBITDA for CP Kelco to £100m from £106m, to account for the incremental costs of operating the business as a standalone entity, the FY25 EBITDA margin remained in line with Barclays (LON:BARC)’ forecast at 17.5%. This improvement, according to Tate & Lyle, reinforces confidence in the phased margin recovery.
Tate & Lyle also confirmed their cost synergy target of $50m, with the goal of achieving 50% by the end of FY26. The cash conversion of more than 75% in FY25 has resulted in proforma net debt to EBITDA ratio of 2.2x at the end of FY25, slightly better than the 2.3x guided at the time of the CP Kelco acquisition.
The company plans to host a Capital Markets Day (CMD) in London on July 1, followed by a site visit to a pectin plant in Denmark.
According to Barclays, while the update is unlikely to materially change consensus estimates for FY25 or FY26, the statement should offer some reassurance—especially given the weak share price performance since the Q3 FY25 guidance downgrade in February—that performance has not deteriorated.